These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10472353)

  • 1. Recent advances in early prostatic cancer.
    Gorgoulis VG; Tiniakos DG; Mariatos G; Manolis EN; Mitropoulos D; Kittas C
    Anticancer Res; 1999; 19(3B):2327-48. PubMed ID: 10472353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual and underappreciated: small cell carcinoma of the prostate.
    Palmgren JS; Karavadia SS; Wakefield MR
    Semin Oncol; 2007 Feb; 34(1):22-9. PubMed ID: 17270662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers.
    Zhou M; Epstein JI
    Pathology; 2003 Dec; 35(6):472-9. PubMed ID: 14660096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract.
    Helpap B
    Cancer; 2002 Oct; 95(7):1415-20. PubMed ID: 12237909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent advances on molecular pathology of prostate carcinoma].
    Niu HL; Tao Y
    Ai Zheng; 2003 May; 22(5):552-6. PubMed ID: 12753724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
    Ohori M
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
    Shariat SF; Karam JA; Margulis V; Karakiewicz PI
    BJU Int; 2008 Mar; 101(6):675-83. PubMed ID: 17941930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making.
    Teixeira MR; Ribeiro FR; Eknaes M; Waehre H; Stenwig AE; Giercksky KE; Heim S; Lothe RA
    Cancer; 2004 Oct; 101(8):1786-93. PubMed ID: 15386312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
    Zeng L; Kyprianou N
    Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine carcinomas of the prostate and urinary bladder: a diagnostic and therapeutic challenge.
    Helpap B; Klöppel G
    Virchows Arch; 2002 Mar; 440(3):241-8. PubMed ID: 11889593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic work-up of the prostate carcinoma].
    Breul J; Paul R
    MMW Fortschr Med; 2006 Nov; 148(44):26-8, 30. PubMed ID: 17619436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.